Kala Pharmaceuticals Inc Forecasted to Earn FY2017 Earnings of ($2.72) Per Share (KALA)
Kala Pharmaceuticals Inc (NASDAQ:KALA) – Equities researchers at Wedbush decreased their FY2017 earnings estimates for Kala Pharmaceuticals in a research report issued to clients and investors on Tuesday. Wedbush analyst L. Moussatos now expects that the company will post earnings per share of ($2.72) for the year, down from their previous estimate of ($2.28). Wedbush currently has a “Buy” rating and a $46.00 target price on the stock. Wedbush also issued estimates for Kala Pharmaceuticals’ Q4 2017 earnings at ($0.43) EPS, FY2018 earnings at ($2.10) EPS and FY2019 earnings at ($1.51) EPS.
Kala Pharmaceuticals (NASDAQ:KALA) last announced its quarterly earnings results on Tuesday, November 7th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.14).
Shares of Kala Pharmaceuticals (KALA) opened at $19.02 on Friday. Kala Pharmaceuticals has a 12 month low of $13.51 and a 12 month high of $26.75. The company has a current ratio of 11.00, a quick ratio of 11.00 and a debt-to-equity ratio of 0.14.
A number of institutional investors have recently bought and sold shares of the business. Orbimed Advisors LLC acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $54,251,000. Caxton Corp acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $12,430,000. Victory Capital Management Inc. acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $12,414,000. OxFORD Asset Management LLP acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $4,374,000. Finally, JPMorgan Chase & Co. acquired a new position in Kala Pharmaceuticals in the third quarter worth approximately $4,037,000. Hedge funds and other institutional investors own 62.96% of the company’s stock.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Receive News & Ratings for Kala Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.